Sign In
Buy NDAQ
$77.65
-3.96 (-4.85%)
At Close: Jun 25, 2026
3 Nasdaq Stocks to Buy Now: Q3 Edition
06:14am, Sunday, 21'st Jul 2024
The Nasdaq Composite lists thousands of publicly-traded stocks in various industries. The index has more than doubled over the past five years and looks like it will continue to march higher.
If You Can Only Buy One Nasdaq Stock in July, It Better Be One of These 3 Names
06:34am, Saturday, 20'th Jul 2024
In the dynamic investing world, selecting standout stocks from the bustling Nasdaq can be a game-changer. As the market navigates through mid-year economic indicators and corporate earnings reports, s
Aptose Announces Receipt of Deficiency Notice from Nasdaq
05:00pm, Friday, 19'th Jul 2024
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing hi
NextTrip, Inc. Receives Nasdaq Notification Regarding Late 10-Q Filing and Continued Listing Requirements
05:00pm, Friday, 19'th Jul 2024
SUNRISE, FL / ACCESSWIRE / July 19, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip," "we," "our," or the "Company"), a travel technology company, received a notice (the "Notice") from the listing qual
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
04:30pm, Friday, 19'th Jul 2024
CAESAREA, Israel , July 19, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alt
Healthcare AI Acquisition Corp. Announces Receipt of Nasdaq Deficiency Letter
04:30pm, Friday, 19'th Jul 2024
NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Healthcare AI Acquisition Corp. (NASDAQ:HAIA) (the "Company"), a special purpose acquisition company, announced today that it received a notification letter
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 19'th Jul 2024
NOVATO, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar
SGI Enhanced Nasdaq-100 ETF, QXQ, NAV Restated
03:32pm, Friday, 19'th Jul 2024
BOUNTIFUL, Utah , July 19, 2024 /PRNewswire/ -- Summit Global Investments announces that the previously disclosed net asset value (NAV) per share of the SGI Enhanced Nasdaq-100 ETF [Ticker: QXQ], cont
5 Non-Tech Nasdaq Stocks to Buy Amid Index's Recent Bloodbath
09:10am, Friday, 19'th Jul 2024
We have narrowed our search to five Nasdaq Composite-listed non-tech stocks. These are: COST, ISRG, IBKR, TXRH, FSLR.
Up 19% Year to Date, Can Gold Outperform the S&P 500 and Nasdaq Composite by the End of 2024?
09:09am, Friday, 19'th Jul 2024
Gold has put up impressive five-year returns. The investment thesis in gold is far different than shares in a company.
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
08:01am, Friday, 19'th Jul 2024
SARASOTA, FL, July 19, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulat
Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
08:00am, Friday, 19'th Jul 2024
SAN DIEGO, July 19, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, announced that it was notified by the Nasdaq Office
S&P 500, Nasdaq Extend Losses As Two Magnificent Seven Stocks Break Key Levels
05:33pm, Thursday, 18'th Jul 2024
The S&P 500 and Nasdaq composite extended losses Thursday, as Magnificent Seven stocks Amazon and Google broke below key levels.
Nasdaq 100: Netflix Beats Q2 Earnings, Falls on Weak Guidance – Tech Stocks Waver
04:47pm, Thursday, 18'th Jul 2024
Netflix Q2 earnings beat expectations, but stock falls on weak Q3 guidance. Tech sector wavers as streaming giant's mixed results impact Nasdaq 100.
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 18'th Jul 2024
BEDFORD, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people's vision and quality of life through
